Discovery of orally active SARS-CoV-2 papain-like protease (PLpro) inhibitors

MR Garnsey, MC Robinson, LT Nguyen, R Cardin… - 2024 - europepmc.org
Vaccines and first-generation antiviral therapeutics have provided important protection
against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory …

Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model

MR Garnsey, MC Robinson, LT Nguyen, R Cardin… - bioRxiv, 2024 - biorxiv.org
Vaccines and first-generation antiviral therapeutics have provided important protection
against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory …

Targeting SARS-CoV-2 papain-like protease in the postvaccine era

AT Ton, M Pandey, JR Smith, F Ban… - Trends in …, 2022 - cell.com
While vaccines remain at the forefront of global healthcare responses, pioneering
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …

Progress and challenges in targeting the SARS-CoV-2 papain-like protease

H Tan, Y Hu, P Jadhav, B Tan… - Journal of medicinal …, 2022 - ACS Publications
SARS-CoV-2 is the causative agent of the COVID-19 pandemic. The approval of vaccines
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …

<? covid19?> High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2

E Smith, ME Davis-Gardner… - … the Science of Drug …, 2020 - journals.sagepub.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late
2019 has triggered an ongoing global pandemic whereby infection may result in a lethal …

Abstract 1713 Shaping antiviral strategies with potent and selective non-covalent SARS-CoV-2 papain-like protease inhibitors

A Al-Homoudi, H Aruri, D Chauhan, O Haskin… - Journal of Biological …, 2024 - ASBMB
SARS-CoV-2 continues to elude containment efforts and remains a significant global health
challenge. There is a critical need for drugs that employ multiple mechanisms of action …

AI-Guided Discovery of Novel SARS-CoV-2 PLpro Inhibitors: Accelerating Antiviral Drug Development in the Fight Against COVID-19

W Spagnoli, WR Danter - bioRxiv, 2023 - biorxiv.org
The global pandemic caused by SARS-CoV-2 has highlighted the urgent need for effective
antiviral drugs. The papain-like protease (PLpro) is a key viral enzyme involved in the …

Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay

C Ma, MD Sacco, Z Xia, G Lambrinidis… - ACS central …, 2021 - ACS Publications
The papain-like protease (PLpro) of SARS-CoV-2 is a validated antiviral drug target.
Through a fluorescence resonance energy transfer-based high-throughput screening and …

Development and application of machine learning-based tools for the discovery of small molecule inhibitors of SARS-CoV-2 papain-like protease (PLpro)

O Garland - 2023 - open.library.ubc.ca
The rapid global spread of the SARS-CoV-2 virus facilitated the development of novel direct-
acting antiviral agents (DAAs) targeting the virus's essential proteins, such as Papain-like …

Potential inhibitors targeting papain-like protease of SARS-CoV-2: two birds with one stone

H Jiang, P Yang, J Zhang - Frontiers in chemistry, 2022 - frontiersin.org
Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), the pathogen of the
Coronavirus disease-19 (COVID-19), is still devastating the world causing significant chaos …